Halozyme Therapeutics | HALO - Ordinary Share Capital

Halozyme Therapeutics reported $135K in Ordinary Share Capital for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Ordinary Share Capital Change
DBV Technologies DBVT:US USD 10.72M 11K
Acadia Pharmaceuticals ACAD:US USD 16K 0
Agios Pharmaceuticals AGIO:US USD 71K 0
Alnylam Pharmaceuticals ALNY:US USD 1.24M 10K
Amarin AMRN:US USD 298.6M 3.94M
Aptinyx Inc APTX:US USD 677K 0
Baxter International BAX:US USD 683M 0
Cara Therapeutics CARA:US USD 53K 0
Cytokinetics CYTK:US USD 94K 1000
Esperion Therapeutics ESPR:US USD 75K 3K
Halozyme Therapeutics HALO:US USD 135K 0
Immunogen IMGN:US USD 2.26M 52K
Intercept Pharmaceuticals ICPT:US USD 42K 1000
Intra Cellular Therapies ITCI:US USD 9K 0
IONIS PHARMACEUT IONS:US USD 142K 0
JAZZ PHA JAZZ:US USD 61K 0
Mannkind MNKD:US USD 2.64M 6K
Minerva Neurosciences NERV:US USD 1000 0
Nektar Therapeutics NKTR:US USD 19K 0
Peregrine Pharmaceuticals PPHM:US USD 62K 0
Rigel Pharmaceuticals RIGL:US USD 174K 1000
United Therapeutics UTHR:US USD 700K 0
Vanda Pharmaceuticals VNDA:US USD 57K 0